CASE REPORT |
|
Year : 2015 | Volume
: 10
| Issue : 1 | Page : 25-26 |
|
Hyperpigmentation, a marker of rifampicin overuse in leprosy patient: An incidental finding
Pugazhenthan Thangaraju, Hosanna Singh, M Punitha, VC Giri, MK Showkath Ali
Division of Clinical and Epidemiology, Central Leprosy Teaching and Research Institute, MOHFW, GOI, Chengalpattu, Tamil Nadu, India
Correspondence Address:
Pugazhenthan Thangaraju Central Leprosy Teaching and Research Institute, Chengalpattu - 603 001, Tamil Nadu India
![Login to access the Email id](http://www.medknow.com/images/email.gif) ![Crossref citations](http://www.medknow.com/journals/images/crossref.png) | Check |
DOI: 10.4103/1858-5000.157506
|
|
We report an unusual case of hyperpigmentation in a 40-year-old female who was on treatment for leprosy with rifampicin 450 mg daily for 2 months. After scrutinizing the treating physician's previous prescriptions and history, it was found that the patient has never taken clofazimine and minocycline, which were considered to cause hyperpigmentation in antileprosy regimen. |
|
|
|
[FULL TEXT] [PDF]* |
|
![Email this article](/ServeContent?url=http%3A%2F%2Fwww.sudanmedicalmonitor.org%2Ftemplates%2Ficon_mail.gif) |
|